Overview

Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
A dose-escalation study to determine the optimum dose of CLAV for effects on craving and efficacy.
Phase:
Phase 1
Details
Lead Sponsor:
Temple University
Collaborators:
Beth Israel Deaconess Medical Center
University of Pennsylvania Perelman School of Medicine
Treatments:
Clavulanic Acid
Clavulanic Acids